Skip to main content
H.R. 7032 117th Congress House

Increasing Transparency in Generic Drug Applications Act of 2022

Official title: To amend section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) with respect to a process to inform persons submitting an abbreviated ap… Show full official titleShow less

Official title: To amend section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) with respect to a process to inform persons submitting an abbreviated application for a new drug whether the new drug is qualitatively or quantitatively the same as a listed drug, and for other purposes.

Introduced: April 1, 2022 See on congress.gov
Health Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 10, 2022
Referred to the Subcommittee on Health.
Mar 9, 2022
Referred to the House Committee on Energy and Commerce.
Mar 9, 2022
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 10, 2022

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Increasing Transparency in Generic Drug Applications Act of 2022

This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).

 Related & companion bills 2
  • HR 7667 Food and Drug Amendments of 2022
  • S 4338 Increasing Transparency in Generic Drug Applications Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 1
All 1 Democratic 1
D
Schrier, Kim
Washington · Apr 1, 2022
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022. 117th Congress. Open America. https://openamerica.io/bill/117-HR-7032/
MLA
"H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-7032/.
Bluebook (legal)
H.R. 7032, 117th Cong. (2026), https://openamerica.io/bill/117-HR-7032/.
Markdown link
[H.R. 7032: Increasing Transparency in Generic Drug Applications Act of 2022](https://openamerica.io/bill/117-HR-7032/)
Report a problem